Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

Jupiter is actively exploring additional strategic partnerships to expand JOTROL’s application across other neuroinflammatory and metabolic disorders, including Alzheimer’s disease and longevity ...

Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based ...

Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied –– Achieved Statistical Significance with Up to 48% Slowing of Clinical ...

JUPITER, FL - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company currently valued at $34.1 million, has announced a partnership with Catalent (NYSE:CTLT) Pharma ...

JUPITER, FL - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company with a market ...

However, if you have a medical condition that affects your driving but don't voluntarily give up your licence, you must ...

Several neuropsychiatric disorders such as attention deficit-hyperactivity disorder (ADHD), autism spectrum disorder (ASD), as well as neurological diseases such as spinocerebellar ataxia type 3 (SCA3 ...

It warns: "You need to tell DVLA about some medical conditions as they can affect your driving. You can be fined up to £1,000 ...

However if you have a medical condition that affects your driving but don't voluntarily give up your licence, you must inform ...

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU.